Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUAL II Japan: IDegLira vs IDeg in T2DM
NCT02911948Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2016
- Primary completion
- Nov 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of insulin degludec + liraglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in Glycosylated Haemoglobin at 26 weeks. Started Sep 2016; status: completed.
02
Drugs
insulin degludec + liraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02911948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02911948.